The rs6265 Polymorphism of the BDNF Gene in the Population of Patients with Multiple Sclerosis in the Tomsk Region

• Published in: Neuroscience and behavioral physiology 2023-11, Vol.53 (9), p.1497-1501
• Main Authors: Titova, M. A., Alifirova, V. M., Kamenskikh, E. M., Musina, N. F., Nikolaeva, T. N., Paderina, D. Z., Boiko, A. S., Ivanova, S. A.
• Format: Article
• Language: English
• Subjects: Behavioral Sciences; Biomedical and Life Sciences; Biomedicine; Brain-derived neurotrophic factor; Chloroform; DNA probes; Gene polymorphism; Genotyping; Methods of Investigation and Diagnostics; Multiple sclerosis; Neurobiology; Neurosciences; Nucleotide sequence; Polymerase chain reaction; Polymorphism
• ISSN: 0097-0549; 1573-899X
• DOI: 10.1007/s11055-023-01544-z

Objectives . To study the effects of the rs6265 polymorphism of the brain-derived neurotrophic factor ( BDNF ) gene on the risk of developing multiple sclerosis (MS), its main clinical characteristics, and the nature of responses to pathogenetic therapy. Materials and methods . The study group consisted of 321 patients and the control group of 266 healthy people. DNA was extracted from venous blood using the standard phenol-chloroform method. Genotyping was carried out by real-time polymerase chain reaction (PCR) using competing TaqMan probes complementary to the polymorphic nucleotide sequence. Results . Carriage of the C allele and the CC genotype of the rs6265 polymorphism of the BDNF gene was found to be a factor determining a more favorable course of MS. Conclusions . Carriers of this genotype had a low rate of progression of MS, a lower frequency of exacerbations, and a less marked degree of disability, while disease duration was comparable; carriers also had a higher frequency of more optimal responses to therapy with first- and second-line MS disease-modifying drugs.